Response to Comments: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

This response-to-comments document (A59063) announces the comment/notice periods and a title revision for MolDX LCD L39017 concerning lab-developed tests for inherited cancer syndromes in patients with cancer, but it does not itself state specific coverage criteria, limitations, documentation requirements, or frequency limits. Review the referenced LCD L39017 (effective 08/21/2022) for authoritative, detailed coverage policy.

"Lab-developed tests (LDTs) for inherited cancer syndromes in patients with cancer are the subject of this policy and are addressed by Local Coverage Determination L39017."

Sign up to see full coverage criteria, indications, and limitations.